Skip to content

The study of brain protection and mechanism of action of Dengzhan Xixin Injection on patients with acute cerebral infarctioX

The study of brain protection and mechanism of action of Dengzhan Xiin Injection on patients with acute cerebral infarction

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17011051
Enrollment
Unknown
Registered
2017-04-04
Start date
2017-04-10
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

Group A:western routine treatment and Dengzhan Xixin Injection
Group B:western routine treatment

Sponsors

Centre for Beijing Aging Brain Rejuvenation initiative.Beijing Normal University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Accord with the diagnostic criteria for acute ischemic stroke in 2014; (2) N1HSS score more than 3 less than 10; (3) Hachinski ischemia scale score more than 4; (4) MMSE score more than 11 less than 26, in accordance with mild or moderate diagnosis of cognition impairment; (5) Aged between 35 to 75 years, men and women; (6) The patients are voluntary to participate in clinical trial and signed the informed consent; (7) There is certain cultural degree;Could read simple articles and write simple sentences.

Exclusion criteria

Exclusion criteria: (1) Recovery and sequelae period of cerebral infarction ,transient ischemic attack (TIA); (2) Cerebral hemorrhage or subarachnoid hemorrhage; (3) Primary dementia, early manifestations of memory impairment, progressive increase, accompanied by other cognitive impairment such as aphasia, loss, loss, and lack of relevant brain imaging examination of focal damage; (4) Confirmed by the brain tumor, brain trauma, blood disease caused by stroke patients; (5) due to rheumatic heart disease, coronary heart disease and other heart disease with atrial fibrillation, causing cerebral embolism; (6) Bone and joint diseases and some other serious diseases which were associated with liver, kidney, hematopoietic system and endocrine system etc; (7) Mental disorders or severe dementia; (8) Patients can not be performed with MRI which has accepted pacemaker surgery, coronary intervention surgery or coronary artery bypass surgery; (9) Allergy to drug used in this trial; (10) Participate in other clinic drug trials.

Design outcomes

Primary

MeasureTime frame
NIH Stroke Scale;Verbal Fluency Test;Stroop Color-word Test;Trail Making Test;Clock Drawing Test;Digit Span Test;Structure MRI;resting-state MRI;diffusion tensor imaging;

Secondary

MeasureTime frame
Activity of Daily living (ADL);Mini-Mental State Examination (MMSE);modified Rankin Scale;Hachinski Scale;

Countries

China

Contacts

Public ContactZhanJun ZHANG

Centre for Beijing Aging Brain Rejuvenation initiative, Beijing Normal University

weidf07@lzu.edu.cn+86 010 58802005

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026